Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer

Oncology Reports

Volumn 7, Issue 3, 2000, Pages 639-644

  Obermair, Andreas ^a,f   Petru, Edgar ^b   Windbichler, Gudrun ^c   Peters Engl, Christian ^a   Graf, Anton H ^d   Stummvoll, Wolfgang ^e   Kaider, Alexandra ^a   Kurschel, Senta ^b   Kölbl, Heinz ^a   Sevelda, Paul ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

^c UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^d St Johanns Spital   (Austria)

^e Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Anemia; Hemoglobin; Ovarian cancer; Prognosis

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD; CANCER STAGING; CARCINOMA; CLINICAL TRIAL; COLLOID CARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; FOLLOW UP; HUMAN; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OVARY TUMOR; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TIME;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANEMIA; CARCINOMA; CARCINOMA, ENDOMETRIOID; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 17044452290     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.3.639     Document Type: Article

References (26)

1. Pettersson F: Annual report on the results of treatment in gynecological cancer. International Federation of Gynecology and Obstetrics, FIGO, Stockholm, 1994.
2. Moliterno AR and Spivak JL: Anemia of cancer. Hematol Oncol Clin North Am 10: 345-363, 1996.
3. Spivak JL: Cancer-related anemia: its causes and characteristics. Semin Oncol 21: 3-8, 1994.
4. Obermair A, Handisurya A, Kaider A, Sevelda P, Kölbl H and Gitsch G: Influence of pretreatment serum hemoglobin levels on survival in epithelial ovarian cancer: a prospective review. Cancer 83: 726-731, 1998.
5. Serov SF, Scully RE and Sorbin LH: Histological typing of ovarian tumors. International Histological Classification of Tumors, WHO, Geneva, 1973.
6. Day TG, Gallager HS and Rutledge FN: Epithelial carcinoma of the ovary: the prognostic importance of histologic grade. Natl Cancer Inst Monograph 42: 15-21, 1975.
7. International Federation of Gynecologists and Obstetricians (FIGO): Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 156: 263-264, 1987.
8. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1985.
9. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
10. Cox DR: Regression models and life tables. J Roy Stat Soc B 34: 187-220, 1972.
11. Piver MS, Barlow JJ and Lele SB: Incidence of subclinical metastasis in stage I and II ovarian carcinoma. Obstet Gynecol 52: 100-104, 1978.
12. Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK and Smith JP: Staging laparotomy in early ovarian cancer. J Am Med Assoc 250: 3072-3076, 1983.
13. Jatzko GR, Lisborg PH, Denk H, Klimpfinger M and Stettner HM: A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan. Cancer 76: 1302-1312, 1995.
14. Logsdon MD and Eifel PJ: Figo IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int J Radiat Oncol Biol Phys 43: 763-775, 1999.
15. Sylvester RJ, Denis L and de Voogt H: The importance of prognostic factors in the interpretation of two EORTC metastatic prostate clinical trials. Eur Urol 33: 134-143, 1998.
16. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, Imbriaco M, Horak I, Conolly M, Ding C, Ouyang P, Kelly WK and Scher HI: Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17: 948-957, 1999.
17. Canaday DJ, Regine WF, Mohiuddin M, Zollinger W, Machtay M, Lee J, Schultz D and Rudoltz MS: Significance of pretreatment hemoglobin level in patients with T1 glottic cancer. Radiat Oncol Invest 7: 42-48, 1999.
18. Ferme C, Bastion Y, Brice P, Lederlin P, Divine M, Gabarre J, Assouline D, Ferrant A, Berger F and Lepage E: Prognosis of patients with advanced Hodkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study. Cancer 80: 1124-1133, 1997.
19. Masuda H, Kurita Y, Fukuta K, Mugiya S, Suzuki K and Fujita K: Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol 5: 418-422, 1998.
20. Dische S: Radiotherapy and anemia - the clinical experience. Radiat Oncol 20 (Suppl): 35-40, 1991.
21. Höckel M, Schlenger KH, Aral B, Mitze M, Schaffer U and Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509-4515, 1996.
22. Thews O, Koenig R, Kelleher DK, Kutzner J and Vaupel P: Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anemia. Br J Cancer 78: 752-756, 1998.
23. Liang BC: Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurol Oncol 29: 149-155, 1996.
24. Eisenhauer EA, Vermorken JB and van Glabbecke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8: 963-968, 1997.
25. Busch RS: The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 12: 2047-2050, 1986.
26. Leitgeb C, Pecherstorfer M, Fritz E and Ludwig H: Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73: 2535-2542, 1994.